Sign in
CompletedPhase 2

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

Key facts

Who runs it
BioNTech SE
Where
Athens, Bridgeton, Charlottesville, Chesterfield, Chicago, Cincinnati, Columbus, East Greenwich, Elmhurst, Farmington Hills, Fort Lauderdale, Galveston, Greenacres City, Hialeah, Hollywood, Honolulu, Houston, Knoxville, Lake Forest, Lincoln, Little River, Miami, Miami Lakes, Monroe, Oak Brook, Oklahoma City, Omaha, Orange, Palmetto Bay, Pembroke Pines, Phoenix, Port Orange, Portsmouth, Raleigh, San Diego, Savannah, Silver Spring, St Louis, Stockbridge, Syracuse, Tomball, Tustin, and Wichita, United StatesSee the 57 sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
1,019 people enrolled
Started
28 Oct 2022
Ended
28 Dec 2023
Type of study
Interventional, 18 groups
Treatments tested
  • bivalent BNT162b2 (original/Omi BA.4/BA.5)
  • qIRV (22/23)
  • QIV
  • bIRV
  • tIRV
Record updated
23 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 40 criteriaShow less

Other criteria

  • SSA: Inclusion Criteria:
  • Male or female participants 18 years of age and older
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
  • Capable of giving signed informed consent as described in the protocol
  • For participants 18 through 64 years of age: participants who have received 3 prior doses of 30 µg BNT162b2, with the last dose being 150 to 365 days before Visit 1 (Day 1)
  • For participants 65 years of age and older: participants who have received 4 or 5 prior doses of a modRNA SARS-CoV-2 vaccine, with the last dose being a bivalent vaccine, 120 days to 365 days before Visit 1 (Day 1)
  • For Participants 65 years of age and older: receipt of licensed influenza vaccination for the 2022-2023 northern hemisphere season 120 days or more before study intervention administration; SSA: Exclusion Criteria:
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Immunocompromised individuals with known or suspected immunodeficiency
  • Bleeding diathesis or condition associated with prolonged bleeding
  • Women who are pregnant or breastfeeding
  • Allergy to egg proteins (egg or egg products) or chicken proteins
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
  • For participants 18 through 64 years of age: vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration
  • Participation in other studies involving a study intervention within 28 days before randomization. Anticipated participation in other studies within 28 days after receipt of study intervention in this study
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
  • Participation in strenuous or endurance exercise through Visit 3 of the study
  • Prior history of heart disease
  • Any abnormal screening troponin I laboratory value
  • Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results; SSB: Inclusion Criteria
  • Male or female participants 18 years of age and older
  • Participants who are willing and able to comply with all scheduled visits, investigational plan, laboratory tests, lifestyle considerations, and other study procedures
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study
  • Capable of giving signed informed consent as described in the protocol
  • Participants who have received at least 3 prior US-authorized mRNA COVID-19 vaccines, with the last dose being an updated (bivalent) vaccine given at least 150 days before Day 1; SSB: Exclusion Criteria
  • Medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality, that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
  • History of severe adverse reaction associated with any vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s)
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Receipt of chronic systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60 days before enrollment through conclusion of the study
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or planned receipt throughout the study
  • Vaccination with any investigational or licensed influenza vaccine within 6 months (175 days) before study intervention administration, or ongoing receipt of chronic antiviral therapy with activity against influenza
  • Participation in other studies involving administration of a study intervention within 28 days prior to, and/or during, participation in this study
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members
  • Initial enrollment only: Participation in strenuous or endurance exercise through Visit 3 (initial enrollment phase)
  • Initial enrollment only: Prior history of heart disease of concern
  • Initial enrollment only: Screening 12-lead ECG that, as judged by the investigator, is consistent with probable or possible myocarditis or pericarditis, or demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results

Where in United States

  • North Alabama Research CenterAthens, United States
  • The Heart CenterAthens, United States
  • Pradeep Chandra, DO, FACCBridgeton, United States
  • Charlottesville Medical ResearchCharlottesville, United States
  • Clinical Research ProfessionalsChesterfield, United States
  • Great Lakes Clinical Trials - RavenswoodChicago, United States
  • CTI Clinical Research CenterCincinnati, United States
  • Centricity Research Columbus Ohio MultispecialtyColumbus, United States
  • Velocity Clinical Research, ProvidenceEast Greenwich, United States
  • Retina AssociatesElmhurst, United States
  • Michigan Center of Medical Research (MICHMER)Farmington Hills, United States
  • Proactive Clinical Research,LLCFort Lauderdale, United States
  • University of Texas Medical BranchGalveston, United States
  • Finlay Medical ResearchGreenacres City, United States
  • Indago Research & Health Center, IncHialeah, United States
  • Research Centers of America (Hollywood)Hollywood, United States
  • East-West Medical Research InstituteHonolulu, United States
  • Prolato Clinical Research CenterHouston, United States
  • Alliance for Multispecialty Research, LLCKnoxville, United States
  • Orange County Research CenterLake Forest, United States
  • Pioneer Heart InstituteLincoln, United States
  • Main Street Physician's CareLittle River, United States
  • McLeod Cardiology Associates - Little RiverLittle River, United States
  • Angels Clinical Research InstituteMiami, United States
  • Entrust Clinical ResearchMiami, United States
  • Gerardo Polanco, MDMiami, United States
  • Jackson Medical Group Cardiac CareMiami, United States
  • Miami Clinical ResearchMiami, United States
  • Miami Dade Medical Research Institute, LLCMiami, United States
  • Research Institute of South FloridaMiami, United States
  • Palm Springs Community Health CenterMiami Lakes, United States
  • Panax Clinical ResearchMiami Lakes, United States
  • Monroe Biomedical ResearchMonroe, United States
  • Affinity HealthOak Brook, United States
  • Alliance for Multispecialty Research, LLCOak Brook, United States
  • Lynn Health Science InstituteOklahoma City, United States
  • Quality Clinical ResearchOmaha, United States
  • Velocity Clinical Research - OmahaOmaha, United States
  • Orange County Heart InstituteOrange, United States
  • Innovation Medical Research CenterPalmetto Bay, United States
  • DBC Research USAPembroke Pines, United States
  • Hope Research InstitutePhoenix, United States
  • The Pain Center of ArizonaPhoenix, United States
  • United Medical ResearchPort Orange, United States
  • ActivMed Practices & Research, LLC.Portsmouth, United States
  • M3 Wake Research, Inc.Raleigh, United States
  • California Research FoundationSan Diego, United States
  • Savannah Medical GroupSavannah, United States
  • Velocity Clinical Research - SavannahSavannah, United States
  • Jadestone Clinical ResearchSilver Spring, United States
  • Sundance Clinical ResearchSt Louis, United States
  • Clinical Research AtlantaStockbridge, United States
  • SUNY Upstate Medical University Institute for Global HealthSyracuse, United States
  • DM Clinical ResearchTomball, United States
  • DM Clinical Research - Martin Diagnostic ClinicTomball, United States
  • Orange County Research CenterTustin, United States
  • Alliance for Multispecialty Research LLCWichita, United States

About the trial

What the trial wants to find out

Substudy A: This is a Phase 1 randomized, open-label study to describe the safety and immunogenicity of up to 3 dose- level combinations of modRNA quadrivalent influenza vaccine (qIRV (22/23)) and bivalent BNT162b2 (original/Omi BA.4/BA.5). Participants will receive either:

Read full original descriptionShow less

* qIRV (22/23)/bivalent BNT162b2 (original/Omi BA.4/BA.5), at 1 of the 3 dose-level combinations * qIRV (22/23) at dose level 1, * qIRV (22/23) at dose level 2, or * bivalent BNT162b2 (original/Omi BA.4/BA.5) at dose level 1 administered concurrently in the opposite arm to commercially licensed quadrivalent influenza vaccine (QIV).

Substudy B: This Phase 1/2 study will describe the safety, tolerability, and immunogenicity of quadrivalent influenza vaccine (qIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), trivalent influenza vaccine (tIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5), and bivalent influenza vaccine (bIRV)/bivalent BNT162b2 (original/Omi BA.4/BA.5) when given concurrently with licensed quadrivalent influenza vaccine (QIV).

The 18 groups in the trial

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 1)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 2)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSA: qIRV + bivalent BNT162b2 (dose level combination 3)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSA: qIRV (dose level 1)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: qIRV (22/23)

  • SSA: qIRV (dose level 2)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: qIRV (22/23)

  • SSA: bivalent BNT162b2 (dose level 1) + QIVTreatment being tested

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and QIV

  • SSB: QIV + bivalent BNT162b2 (original/Omi BA.4/BA.5)Treatment being tested

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and QIV

  • SSB: QIV + bIRV/bivalent BNT162b2 (original/Omi BA.4/BA.5)Treatment being tested

    BNT162b2 administered intramuscularly into the deltoid muscle of the right arm, QIV administered intramuscularly into the deltoid muscle of the left arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5), QIV, and bIRV

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 1Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 2Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 3Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 4Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 5Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 6Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 7Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: qIRV/bivalent BNT162b2 (original/ Omi BA.4/BA.5) at dose-level combination 8Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and qIRV (22/23)

  • SSB: tIRV/bivalent BNT162b2(original/Omi\BA.4/BA.5)Treatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: bivalent BNT162b2 (original/Omi BA.4/BA.5) and tIRV

  • SSB: qIRVTreatment being tested

    Administered intramuscularly into the deltoid muscle of the right arm

    Treatment: qIRV (22/23)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 1/2 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID-19 AND INFLUENZA IN HEALTHY INDIVIDUALS
Record updated
23 July 2025